Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Durante C, Russo D, Verrienti A, et al, “XL184 (Cabozantinib) for Medullary Thyroid Carcinoma,” Expert Opin Investig Drugs , 2011, 20(3):407-13. [PubMed 21314233 ] Kurzrock R, Sherman SI, Ball DW, et al, “Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer,” J Clin Oncol , 2011, 29(19):2660-6. [PubMed 21606412 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Smith DC, Smith MR, Sweeney C, et al, “Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial,” J Clin Oncol , 2013, 31(4):412-9. [PubMed 23169517 ] Yakes FM, Chen J, Tan J, et al, “Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth,” Mol Cancer Ther , 2011, 10(12):2298-308. [PubMed 21926191 ] Topic 87299 Version 11.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]